MedTrace Logo

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

NCT03095781 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.

Conditions

  • Colorectal Adenocarcinoma
  • Metastatic Pancreatic Adenocarcinoma
  • Recurrent Colorectal Carcinoma
  • Recurrent Pancreatic Carcinoma
  • Stage III Colorectal Cancer
  • Stage III Pancreatic Cancer
  • Stage IIIA Colorectal Cancer
  • Stage IIIB Colorectal Cancer
  • Stage IV Colorectal Cancer
  • Stage IV Pancreatic Cancer
  • Stage IVA Colorectal Cancer
  • Stage IVA Pancreatic Cancer
  • Stage IVB Colorectal Cancer
  • Stage IVB Pancreatic Cancer
  • Unresectable Pancreatic Carcinoma

Interventions

DRUG

XL888

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Exelixis

    collaborator INDUSTRY

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Maria Diab, MD · Emory University/Winship Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-07
Primary Completion
2021-06-10
Completion
2021-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03095781 on ClinicalTrials.gov